Related Experiment Videos
[Changes in thrombocytic hemostasis in patients with diabetic glomerulosclerosis]
Insights
Diabetic glomerulosclerosis with kidney issues often shows hypercoagulation. Monitoring thrombocytic hemostasis and specific tests can guide treatment for diabetes mellitus complications.
Area of Science:
- Nephrology
- Hematology
- Endocrinology
Context:
- Diabetic glomerulosclerosis is a significant complication of diabetes mellitus.
- Chronic renal insufficiency frequently accompanies advanced diabetic glomerulosclerosis.
- Thrombocytic hemostasis plays a crucial role in the pathophysiology of vascular complications.
Purpose:
- To investigate thrombocytic hemostasis indices in patients with diabetic glomerulosclerosis and chronic renal insufficiency.
- To correlate hemostasis changes with clinical manifestations of diabetes mellitus and its renal complications.
- To identify key tests for guiding treatment strategies in affected patients.
Summary:
- Patients with diabetic glomerulosclerosis and chronic renal insufficiency exhibit signs of hypercoagulation.
- Thrombocytic hemostasis alterations were diverse, showing a strong correlation with clinical diabetes mellitus and glomerulosclerosis.
- Recommended diagnostic tests include the hemolysate-aggregation test, soluble complexes of monomer fibrin, and fibrin-splitting products.
Impact:
- Provides insights into the hypercoagulable state associated with diabetic glomerulosclerosis.
- Highlights the link between hemostasis abnormalities and disease progression.
- Suggests specific tests for improved clinical management and treatment selection for patients with diabetic kidney disease.
Abstract:
Indices of thrombocytic hemostasis were determined in 40 patients with diabetic glomerulosclerosis. It was found that patients suffering of diabetic glomerulosclerosis with chronic renal insufficiency showed signs of hypercoagulemia while changes of the thrombocytic hemostasis become of diverse values. There was a high correlation of hemostasis changes and clinical manifestations of diabetes mellitus and diabetic glomerulosclerosis. Three tests are recommended for treatment choice: hemolysate-aggregation test, determination of soluble complexes of monomer fibrin and fibrin-splitting product.